In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin

Annals of Clinical Microbiology and Antimicrobials

Volumn 15, Issue 1, 2016, Pages

  Herrera, Melina ^a   Di Gregorio, Sabrina ^b   Fernandez, Silvina ^b   Posse, Graciela ^a   Mollerach, Marta ^b   Di Conza, José ^a,b,c  

^a Universidad Adventista del Plata   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Efflux activity; MRSA; Tigecycline resistant; VISA

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; OXACILLIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG RESISTANCE; EFFUSION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MUTATION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 85007414026     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-016-0131-7     Document Type: Article

References (27)

1. Chambers HF, De Leo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-41.
2. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104:7-10.
3. Chang S, Sievert D, Hageman J, Boulton M, Tenover F, Downes F, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-7.
4. Stein G, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75:331-6.
5. Hoban D, Reinert R, Bouchillon S, Dowzicky M. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004-2013. Ann Clin Microbiol Antimicrob. 2015;10:14-27.
6. Garza-González E, Dowzicky M. Changes in Staphylococcus aureus susceptibility across Latin America between 2004-2010. Braz J Infect Dis. 2013;17:13-9.
7. Balode A, Punda-Polic V, Dowzicky M. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int J Antimicrob Agents. 2013;41:527-35.
8. Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from US medical centers since its approval for clinical use (2006-2012). Antimicrob Agents Chemother. 2014;58:2274-80.
9. Hallin M, Deplano A, Denis O, De Mendonça R, De Ryck R, Struelens MJ. Validation of pulsed-field gel electrophoresis and spa typing for longterm, nationwide epidemiological surveillance studies of Staphylococcus aureus infections. J Clin Microbiol. 2007;45:127-33.
10. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother. 2007;51:264-74.
11. Gilot P, Lina G, Cochard T, Poutrel B. Analysis of the genetic variability of genes encoding the RNA III-activating components agr and TRAP in a Population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol. 2002;40:4060-7.
12. Traber KE, Lee E, Benson S, Corrigan R, Cantera M, Shopsin B, et al. agr function in clinical Staphylococcus aureus isolates. Microbiology. 2008;154:2265-74.
13. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother. 2005;49:1865-71.
14. Chung M, de Lencastre H, Matthews P, Tomasz A, Adamsson M, Aires de Sousa M, et al. Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains. Microb Drug Resist. 2000;6:189-98.
15. Patel D, Kosmidis C, Seo SM, Kaatz G. Ethidium bromide MIC screening for enhanced efflux pump gene expression or efflux activity en Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5070-3.
16. DeMarco CE, Cushing LA, Frempong-Manso E, Seo SM, Jaravaza TA, Kaatz GW. Efflux-related resistance to norfloxacin, dyes and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3235-9.
17. Huet A, Raygada J, Mendiratta K, Seo S, Kaatz G. Multidrug efflux pumps overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes. Microbiology. 2008;154:3144-53.
18. Santos Costa S, Viveiros M, Amaral L, Couto I. Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J. 2013;7:59-71.
19. Naimi TS, Anderson D, O'Boyle C, Boxrud DJ, Johnson SK, Tenover FC, et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003;36:1609-12.
20. Siradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for a chemotherapy. J Clin Microbiol. 2003;41:1687-93.
21. Sola C, Cortes P, Saka HA, Vindel A, Bocco JL. Evolution and molecular characterization of methicillin-resistant Staphylococcus aureus epidemic and sporadic clones in Cordoba. Argentina. J Clinical Microbiol. 2006;44:192-200.
22. Gardella N, von Specht M, Curiolo A, Rosato A, Gutkind G, Mollerach M. Community-associated methicillin-resistant Staphylococcus aureus, eastern Argentina. Diagn Microbiol Infect Dis. 2008;62:343-7.
23. Howe RA, Monk A, Wotton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis. 2004;10:855-7.
24. Kos VN, Desjardins CA, Griggs A, Cerqueira G, Van Tonder A, Holden MT, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with methicillin-resistant S. aureus hospital-acquired infection in the United States. M Bio. 2012; doi: 10.1128/mBio.00112-12.
25. Di Gregorio S, Perazzi B, Ordoñez AM, De Gregorio S, Foccoli M, Lasala MB, et al. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist. 2015;21:25-34.
26. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis. 2003;187:929-38.
27. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002;46:1492-502.